Antidote Technologies, a digital patient engagement company, announced it is partnering with SEQSTER, a multidimensional healthcare data platform, to identify patients for clinical trials and improve trial timelines.
Antidote offers a clinical trial patient-recruitment platform that includes patient screening and support services.
The company will leverage SEQSTER’s operating system to better match patients to clinical trials based on their genomic data, lifestyle factors and medical history.
“Partnering with SEQSTER allows us to enhance our precision recruitment process with unparalleled data integration capabilities, ensuring that we can more effectively identify suitable participants and reduce the time it takes to bring new treatments to market,” Samantha Veeck, co-CEO of Antidote, said in a statement.
THE LARGER TREND
In December, San Diego-based SEQSTER partnered with Palo Alto-based real-world data platform Atropos Health to improve diversity and inclusion in clinical trials by creating turnkey patient registries to accelerate the generation of evidence.
In March, SEQSTER partnered with the Multiple Sclerosis Association of America to use data to bring together people living with MS, researchers and care centers nationwide.
Three months later, decentralized clinical trial company Thread and SEQSTER partnered to access real-world data for life science enterprises, researchers and patients.
Another company focused on enhancing the clinical trial experience is oncology-focused digital health company Flatiron Health, which Roche acquired in 2018.
In May, Flatiron announced a strategic collaboration with the Association of Cancer Care Centers to promote access to clinical trials in the community setting, improve clinical study efficiency and enhance the gathering of study-related data.
Clinical trial startup Inato, the Digital Medicine Society (DiMe), clinical trial tech company Science 37 and tech-enabled clinical trial platform Paradigm are also players in the space.
